細胞表面タンパク質CD47の阻害は、近年、学界と産業界の両方の関心をそそる新しいがん免疫療法アプローチとして浮上しています。がん細胞はしばしばCD47を過剰発現し、それが「私を食べないで」というシグナル経路を誘発し、それによって悪性細胞が免疫監視から逃れるのを助けます。CD47阻害剤は、このタンパク質を阻害することによりがん細胞を発見し、特にマクロファージ食作用の増加を通じて免疫系の攻撃に対してがん細胞を開放しようとします。現在、CD47阻害剤は治療薬として承認されていませんが、第3相試験で候補が入手可能であることから、今後数年以内に承認される可能性が示唆されています。
目次
Table of Content
1. CD 47 As Novel Cancer Immunotherapy Target
2. Global CD47 Inhibitors Drug Clinical Pipeline Overview
2.1 By Country
2.2 By Company
2.3 By Indication
2.4 By Patient Segment
2.5 By Phase
2.6 By Priority Status
3. CD47 Inhibitors Clinical Trials Insight By Company, Country, Indication and Phase
3.1 Research
3.2 Preclinical
3.3 Phase I
3.4 Phase I/II
3.5 Phase II
3.6 Phase II/III
3.7 Phase III
4. Global CD47 Inhibitor Drug Market Opportunity Outlook
4.1 Current Market Overview
4.2 Future Outlook and Opportunities
5. CD47 Clinical Application and Development Outlook by Indication 5.1 Solid Cancers
5.1.1 Breast Cancer
5.1.2 Colorectal Cancer
5.1.3 Lung Cancer
5.1.4 Urogenital Cancer
5.1.5 Gastrointestinal Cancer 5.2 Hematological Malignancies
5.2.1 Lymphoma 5.2.2 Leukemia
5.2.3 Multiple Myeloma
5.2.4 Myelodysplastic Syndrome 5.3 Microbial Infections
6. CD47 Inhibitor Drugs Clinical Developments and Trends By Country
6.1 China
6.2 US
6.3 South Korea
6.4 Australia
6.5 Canada
7. Global CD47 Inhibitors Market Dynamics
7.1 Favorable Parameters
7.2 Market Restraints
8. Competitive Landscape
8.1 Adagene
8.2 ALX Oncology
8.3 ImmuneOncia Therapeutics
8.4 ImmuneOnco Biopharma
8.5 Light Chain Bioscience
8.6 Phanes Therapeutics
8.7 Virtuoso Therapeutics
List of Figures
List of Figures
Figure 2-1: Global - Number of CD47 Inhibitor Drugs Clinical Trial By Country, 2022 Till 2028
Figure 2-2: Global - Number of CD47 Inhibitor Drugs In Clinical Pipeline By Company, 2022 Till 2028
Figure 2-3: Global - Number of CD47 Inhibitor Drugs In Clinical Pipeline By Indication, 2022 Till 2028
Figure 2-4: Global - Number of CD47 Inhibitor Drugs In Clinical Pipeline By Patient Segment, 2022 Till 2028
Figure 2-5: Global - Number of CD47 Inhibitor Drugs In Clinical Pipeline By Phase, 2022 Till 2028
Figure 2-6: Global - Number of CD47 Inhibitor Drugs In Clinical Pipeline By Priority Status, 2022 Till 2028
Figure 5-1: NI-1801 Phase I Study (NCT05403554) - Initiation and Completion Year
Figure 5-2: ALX148 Phase I Study (NCT05868226) - Initiation and Completion Year
Figure 5-3: Ligufalimab Phase II Study (NCT05382442) - Initiation and Completion Year
Figure 5-4: PT217 Phase I/II Study (NCT05652686) - Initiation and Completion Year
Figure 5-5: HMPL-A83 Phase I Study (NCT05429008) - Initiation and Completion Year
Figure 5-6: ALX148 Phase I Study (NCT05524545) - Initiation and Completion Year
Figure 5-7: PT217 Phase I/II Study (NCT05652686) - Initiation and Completion Year
Figure 5-8: AK117 Phase II Study (NCT05382442) - Initiation and Completion Year
Figure 5-9: AK117 Phase I/II Study (NCT05214482) - Initiation and Completion Year
Figure 5-10: AK117 Phase II Study (NCT05960955) - Initiation and Completion Year
Figure 5-11: Evorpacept Phase II/III Study (NCT05002127) - Initiation and Completion Year
Figure 5-12: PT886 Phase I/II Study (NCT05482893) - Initiation and Completion Year
Figure 5-13: CC-96673 Phase I Study (NCT04860466) - Initiation and Completion Year
Figure 5-14: HCB101 Phase I Study (NCT05892718) - Initiation and Completion Year
Figure 5-15: Evorpacept Phase I/II Study (NCT05025800) - Initiation and Completion Year
Figure 5-16: AK117 Phase I/II Study (NCT04980885) - Initiation and Completion Year
Figure 5-17: AK117 Phase I/II Study (NCT06387420) - Initiation and Completion Year
Figure 5-18: TQB 2928 Phase I Study (NCT06008405) - Initiation and Completion Year
Figure 5-19: SL-172154 Phase I Study (NCT05275439) - Initiation and Completion Year
Figure 5-20: SL-172154 Phase Ib Study (NCT05275439) - Initiation and Completion Year
Figure 5-21: Ligufalimab Phase Ib Study (NCT04900350) - Initiation and Completion Year
Figure 6-1: South Korea - Prominent CD47 Inhibitor Developers
Figure 7-1: Global CD47 Inhibitors Market - Drivers and Opportunities
Figure 7-2: Global CD47 Inhibitors Market - Challenges and Restraints
List of Tables
Table 5-1: Breast Cancer - Some CD47 inhibitors In Clinical Trials
Table 5-2: Colorectal Cancer - Some CD47 inhibitors In Clinical Trials
Table 5-3: Lung Cancer - Some CD47 inhibitors In Clinical Trials
Table 5-4: Urogenital Cancer - Some CD47 inhibitors In Clinical Trials
Table 5-5: Gastrointestinal Cancer - Some CD47 inhibitors In Clinical Trials
Table 5-6: Lymphoma - Some CD47 inhibitors In Clinical Trials
Table 5-7: Leukemia - Some CD47 inhibitors In Clinical Trials
Table 5-8: Colorectal Cancer - Some CD47 inhibitors In Clinical Trials
Table 5-9: Myelodysplastic Syndrome - Some CD47 inhibitors In Clinical Trials
